Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

Zanidatamab is the first agent approved specifically for advanced, HER2-positive second-line biliary tract cancer.

Unlock your investing potential with TipRanks Premium - Now At 40% OFF!

China’s NRDL includes Akeso’s two bispecific antibody drugs, cadonilimab & ivonescimab: Hong Kong Friday, November 29, 2024, 10:00 Hrs [IST] Akeso, Inc., a leading biopharmace ...

Global Bispecific Antibody Is Expected To Surpass US$ 40 Billion By 2029 Says Kuick ResearchDelhi, Nov. 25, 2024 (GLOBE ...

The new drug, Jazz Pharmaceuticals’ zanidatamab, has won an FDA accelerated approval for adults with previously treated ...

The successful completion of this round of financing marks a pivotal moment in AllinkBio's growth trajectory. With the new financial resources in place, combined with the company's efficient R&D ...

Nectin-4 antibody-drug conjugate (ADC) and checkpoint inhibitor combinations have represented a great advancement in the treatment of bladder cancer, but relapse and treatment-related toxicities ...

The funds will be utilised to progress the global clinical development of Allink's lead candidates, ALK201 and ALK202.

The successful completion of this round of financing marks a pivotal moment in AllinkBio's growth trajectory. With the new financial resources in place, combined with the company's efficient R&D ...

A decade after the discovery of CALR, the results are the first for a possible therapy for CALR-mutated MPNs to reach the ...